Future therapies can potentially not only affect the cellular fate of the cell by dysregulating iron metabolism, as was already proved feasible by inhibiting DMT1 in cancer stem cells [131], but could also evoke a shift in a variety of processes accompanying cell transformation, including its development, inflammation, immune responses, wound healing and cancer progression [130]. This evidence concerns the gene SLC11A2 and cancer.